We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Celgene Sues Barr Over Generic Thalomid

Law360 (August 27, 2007, 12:00 AM EDT) -- Celgene Corp. has filed another patent suit against Barr Pharmaceuticals Inc. in an attempt to stave off generic competition for its lucrative cancer treatment Thalomid, which brought in $117.7 million in net sales in the second quarter of 2007.

Celgene filed the lawsuit Thursday in the U.S. District Court for the District of New Jersey, naming Barr Laboratories Inc. and Barr Pharmaceuticals Inc. as defendants. Celgene had already sued Barr over Thalomid in January, but Thursday's suit accuses Barr of infringing U.S. Patent Number 7,230,012, which...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.